Division of Pediatric Surgery, Stollery Children's Hospital, University of Alberta Hospital, Edmonton, Alberta, Canada.
J Pediatr Surg. 2011 Aug;46(8):1618-30. doi: 10.1016/j.jpedsurg.2011.04.002.
Intestinal failure (IF) is the dependence upon parenteral nutrition to maintain minimal energy requirements for growth and development. It may occur secondary to a loss of bowel length, disorders of motility, or both. Short bowel syndrome (SBS) is a malabsorptive state resulting from surgical resection, congenital defect, or diseases associated with loss of absorptive surface area. A particularly vexing problem is associated with whole bowel and/or segmental intestinal dysmotility. Motility disorders within the context of SBS and IF may relate to rapid intestinal transit secondary to loss of intestinal length, dysmotility associated with loss or poor antegrade peristalsis, or gastroparesis. Therapy may be classified into medical (prokinetic and antidiarrheal agents) and surgical to deal with the overdistended poorly motile bowel.
We performed a systematic review of the literature pertaining to IF, SBS, and dysmotility in the pediatric population with gastroschisis, necrotizing enterocolitis, and intestinal atresia. In addition to the available treatment options, we have provided a review of the literature and a summary of the available evidence.
Despite relatively poor level of evidence regarding the application of promotility and antidiarrheal medications in patients with SBS and IF, these agents continue to be used. Herein, we provide a review of the physiology and pathophysiology of intestinal motility/dysmotility and available strategies for the use of promotility and antidiarrheal agents in patients with IF/SBS.
肠衰竭(IF)是指依靠肠外营养来维持生长和发育的最低能量需求。它可能是由于肠段丢失、运动障碍或两者共同导致的。短肠综合征(SBS)是一种吸收不良状态,由手术切除、先天性缺陷或与吸收表面积丧失相关的疾病引起。一个特别令人困扰的问题与全肠和/或节段性肠运动障碍有关。SBS 和 IF 中的运动障碍可能与肠段丢失导致的快速肠转运、与蠕动丧失或不良的向前蠕动相关的运动障碍、或胃轻瘫有关。治疗可分为医学(促动力和抗腹泻药物)和手术,以应对过度扩张和运动不良的肠道。
我们对患有先天性腹裂、坏死性小肠结肠炎和肠闭锁的儿科患者的 IF、SBS 和运动障碍进行了系统的文献回顾。除了现有的治疗选择外,我们还对文献进行了回顾,并对现有证据进行了总结。
尽管关于 SBS 和 IF 患者使用促动力和抗腹泻药物的证据水平相对较低,但这些药物仍在继续使用。在此,我们对肠运动/运动障碍的生理学和病理生理学以及在 IF/SBS 患者中使用促动力和抗腹泻药物的可用策略进行了综述。